Upstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge Concerns
Upstream Bio Inc. (NASDAQ:UPB) shares are trading lower during Friday’s session as the stock reacts to recent developments in its clinical trials.
Over the last few days, the stock has plunged more than 54%.
The decline follows a report highlighting the company’s results for its asthma treatment.
VALIANT Trial Shows 56% Reduction in Asthma Attacks
The VALIANT trial demonstrated statistically significant reductions in the annualized asthma exacerbation rate (AAER) of 56% for the 100 mg every 12 weeks dosing compared to placebo.
Additionally, the drug showed improvements in lung function and was well-tolerated, with over 90% of eligible patients transitioning to the long-term extension study.
Analyst Take
William Blair, in an investor note on Wednesday, wrote, “While the biomarker results looked strong at both the 100 mg Q3M and 400 mg Q6M arms for verekitug, the lower exacerbation reduction seen at 400 mg Q6M has raised concerns on the competitive positioning of verekitug versus others in Phase II/III development.”
The broader market experienced a mixed performance on the previous trading day, with the Healthcare sector remaining flat, gaining 0.00%. Upstream Bio’s decline comes as the broader market showed resilience, suggesting that company-specific factors may be influencing the stock’s movement.
Analyst Matt Phipps wrote that shares trading down almost 50% ‘is overdone’, as some investors view the thymic stromal lymphopoietin (TSLP) space
as a winner-take-all for the one who can first commercialize a Q6M dosing regimen
UPB Stock Shows Strong Short-Term Momentum
Currently, the stock is trading 10.2% above its 20-day simple moving average (SMA) and 30.5% above its 100-day SMA, indicating strong short-term momentum. Over the past 12 months, shares have surged 292.24% and are currently positioned closer to their 52-week highs than lows.
The RSI is at 45.37, which is considered neutral territory, while MACD is below its signal line, indicating bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum.
- Key Resistance: $33.50
- Key Support: $12.00
Analyst Consensus & Recent Actions:
The stock carries a Strong Buy rating with an average price forecast of $49.00. Recent analyst moves include:
- Mizuho: Initiated with Outperform (Target $51.00) (Dec. 18, 2025)
- LifeSci Capital: Initiated with Outperform (Target $43.00) (Dec. 2, 2025)
- Evercore ISI Group: Initiated with Outperform (Target $40.00) (Nov. 18, 2025)
UPB Price Action: Upstream Bio shares were down 11.33% at $12.69 at the time of publication on Friday.
Photo by JPC_PROD via Shutterstock
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jiayin Technology (JFIN.US) Holds 500 Million Cash in First Half of Year, Overseas Market Bet Becomes the Key to Breakthrough
Jiayin Financial Technology (JFIN.US) released its financial report for the first half of 2026, reporting revenue of 1.494 billion yuan, gross profit of 613 million yuan, and a gross margin of 41.03%.

The electricity equipment giant priced as a software stock? GE Vernova (GEV.US) faces a short attack from GLJ; Bernstein responds: It's not just data centers, utilities are the real trump card.
After experiencing a sharp decline on Monday, GE Vernova stabilized on Tuesday. However, debates surrounding this power equipment giant are intensifying in the market.

The "AI slowdown theory" can't stop the funding frenzy of model giants! Astra is launched, sparking heated discussions on AGI; OpenAI aims for a $1.2 trillion valuation
OpenAI is in early talks with investors to discuss a new round of financing, which would bring the valuation of ChatGPT's creator OpenAI to over $1.2 trillion. The company will subsequently conduct its initial public offering (IPO).

White House Pressure Fails to Prevent Hawkish Shift! Federal Reserve Rate Hike Looms, Waller-Trump Relationship Faces Major Test
The Federal Reserve is expected to raise interest rates by 25 basis points on Wednesday, marking the first increase since 2023; the market is pricing in a probability of over 90%, and the relationship between the White House and Walsh faces a test.

